Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × INDUSTRY × Chalazion × Clear all

Phase

Phase NA 3 Phase 4 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 57 Breast Neoplasms 56 Prostatic Neoplasms 39 Carcinoma, Non-Small-Cell Lung 38 Neoplasm Metastasis 20 Colorectal Neoplasms 19 Pain 17 Multiple Myeloma 16 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16 Anemia 14 Keratosis, Actinic 13 Cancer Pain 12 Lung Neoplasms 11 Lymphoma, Non-Hodgkin 10 Leukemia 10 Carcinoma, Renal Cell 10 Lymphoma, Follicular 9 Leukemia, Lymphocytic, Chronic, B-Cell 9 Carcinoma, Hepatocellular 9 Carcinoma 9 Melanoma 8 Lymphoma 7 Uterine Cervical Neoplasms 6 Recurrence 6 Ovarian Neoplasms 6 Neuroendocrine Tumors 6 Leukemia, Myeloid, Acute 6 Stomatitis 5 Lymphoma, T-Cell, Cutaneous 5 Leukemia, Myeloid, Chronic-Phase 5

Interventions

Loteprednol Etabonate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00420628 2011-10-07

Pediatric Zylet Safety and Efficacy Study

Bausch & Lomb Incorporated

Phase 4 Completed

108 enrolled 11 charts

Hordeolum, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡